Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Colestipol May Quickly Eliminate Teriflunomide
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Sanofi MS drug nears green light after pass-the-parcel marathon
Pharmacokinetic properties and metabolism of idebenone.
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Laquinimod Phase IIa Study in Active Crohn's Disease
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Reactive astrocytes as therapeutic targets for CNS disorders.
Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis.
Tecfidera(®): an approach for repurposing.
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Treatment of acute transverse myelitis and its early complications.
Immunology 2013
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.

Pages